Journal of Cardiovascular Pharmacology最新文献

{"title":"Drug-Induced Spontaneous Intramural Hematoma of the Gastrointestinal Tract: A Real-World Pharmacovigilance Analysis.","authors":"Xuehong Wang, Min Luo, Wenyu Li, Yuqian Zhou","doi":"10.1097/FJC.0000000000001662","DOIUrl":"10.1097/FJC.0000000000001662","url":null,"abstract":"<p><strong>Abstract: </strong>It is unclear whether drugs other than warfarin can cause spontaneous gastrointestinal intraluminal hematomas (SGIH). This study aimed to investigate the drugs that induced SGIH based on the US Food and Drug Administration's Adverse Event Reporting System data. A retrospective pharmacovigilance study was conducted. The disproportionality analysis was performed to assess the reports of drug-induced SGIH from the first quarter of 2004 to the fourth quarter of 2023. Logistics regression analysis was used to explore drug-related SGIH risk factors. Weibull distribution was applied for the onset time of SGIH. A total of 116 drugs associated with SGIH have been reported in the US Food and Drug Administration's Adverse Event Reporting System database. After removing duplicates, 88 unique drugs involving 210 patients were identified. These drugs can be broadly classified into 4 categories: (1) anticoagulants, (2) new direct oral anticoagulants, (3) antiplatelet agents, and (4) others. The first group is dominated by warfarin (59/210), while the second group, rivaroxaban, accounts for the most significant proportion (9/210). As for the third group, aspirin is the dominant drug (16/210), and for the fourth group, drugs that cause thrombocytopenia are dominant. The median number of reported cases was 11.5 per year, accounting for a median percentage of 0.0094% of all adverse events related to target drugs. The median time to drug-related SGIH onset was 12.5 days (interquartile range 1-220.25 days). When patients on the related drugs present with corresponding abdominal symptoms, it is crucial to consider the differential diagnosis of SGIH despite its low incidence.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"297-304"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine in Coronary Artery Disease: Where Do We Stand?","authors":"Aldo Bonaventura, Nicola Potere, Luca Liberale, Simon Kraler, Brittany N Weber, Antonio Abbate","doi":"10.1097/FJC.0000000000001672","DOIUrl":"10.1097/FJC.0000000000001672","url":null,"abstract":"<p><strong>Abstract: </strong>Colchicine is an anti-inflammatory drug for different inflammatory conditions and is approved for secondary prevention of cardiovascular events in patients with coronary artery disease, mainly based on the results of the LODOCO2 and COLCOT trials. The recently published CLEAR SYNERGY trial reported neutral results for colchicine in patients with acute myocardial infarction undergoing percutaneous coronary intervention, challenging the previous reported benefits of colchicine. While colchicine appeared rather safe across the different studies, the variation in efficacy may suggest that the one-size-fits-all for the treatment of acute and chronic forms of coronary artery disease may not be appropriate, and that low-dose colchicine may be beneficial as an add-on therapy in patients who are stable or recovering from acute event, and not so helpful in patients with acute myocardial infarction already receiving intensive pharmaco-invasive therapies.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"243-247"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes for 2025 at Journal of Cardiovascular Pharmacology: Introducing Our Junior Associate Editors, Podcasts, Feature, and New Board Members.","authors":"Antonio Abbate, Giuseppe Biondi-Zoccai, Raffaele Altara, George W Booz","doi":"10.1097/FJC.0000000000001673","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001673","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":"85 4","pages":"239-242"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcome Measures in Cardiovascular Research and Care: PRO(M)s and CONS.","authors":"Giuseppe Biondi-Zoccai, Giacomo Frati, Mariangela Peruzzi, Marco Bernardi, Luigi Spadafora, Elena Tremoli","doi":"10.1097/FJC.0000000000001669","DOIUrl":"10.1097/FJC.0000000000001669","url":null,"abstract":"<p><strong>Abstract: </strong>Patient-reported outcome measures (PROMs) are vital tools in cardiovascular disease research and care, providing insights that complement traditional clinical outcomes such as mortality and morbidity. PROMs capture patient experiences with cardiovascular disease, such as quality of life, functional capacity, and emotional well-being, allowing clinicians to assess how interventions affect daily life. PROMs are integral to cardiovascular investigations and management, especially in chronic conditions and rehabilitation, where they inform on the impact of personalized care plans by tracking symptom progression and patient adherence. Selecting and applying to cardiovascular research and practice effective PROMs involves evaluating their validity, reliability, and sensitivity to change, with instruments such as the Kansas City Cardiomyopathy Questionnaire and the Seattle Angina Questionnaire widely used for heart failure and coronary artery disease, respectively. Implementing PROMs in real-world practice requires addressing challenges related to workflow integration and patient adherence, emphasizing their value in patient-centered care. As digital health advances, remote PROM data collection through mobile applications and wearable devices will enhance access to and extent of PROMs, and artificial intelligence-driven analytical tools will provide real-time, automated and plausible more poignant insights for personalized treatment. Future efforts should focus on culturally adapting PROMs for diverse populations to ensure global applicability. PROMs should also be established as essential components of innovative research and responsive, patient-centered cardiovascular care.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"261-266"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latest Evidence and Perspectives of Panax Notoginseng Extracts and Preparations for the Treatment of Cardiovascular Diseases.","authors":"Chenyu Zhao, Jiamei Fu, Yingyu Wang, Yabin Zhou","doi":"10.1097/FJC.0000000000001670","DOIUrl":"10.1097/FJC.0000000000001670","url":null,"abstract":"<p><strong>Abstract: </strong>Cardiovascular diseases are a major cause of death worldwide, and their high incidence poses a significant threat to human health and public health systems. Panax notoginseng , a traditional Chinese medicinal herb with a long history, has shown promise in treating cardiovascular diseases. This review examines the diverse mechanisms through which Panax notoginseng addresses cardiovascular diseases, including anti-inflammatory, antiplatelet aggregation, anticoagulation, anti-oxidative stress, regulation of angiogenesis, antiatherosclerosis, improvement of microcirculatory disorders, and protection against myocardial ischemia-reperfusion injury, highlighting saponins as the principal active components. It also summarizes studies involving Panax notoginseng preparations like Xueshuantong and Xuesaitong in treating coronary heart disease and myocardial infarction, and discusses the safety, limitations, and future research directions of these extracts. In conclusion, the cardiovascular protective mechanism of Panax notoginseng is multitargeted and multipathways, and its clinical application is relatively safe, with rare and mild adverse drug reactions, suggesting a promising therapeutic potential.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"248-260"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activation of APJ Receptors by CMF-019, But Not Apelin, Causes Endothelium-Dependent Relaxation of Spontaneously Hypertensive Rat Coronary Arteries.","authors":"Santo Anto, Chengwen Sun, Stephen T O'Rourke","doi":"10.1097/FJC.0000000000001671","DOIUrl":"10.1097/FJC.0000000000001671","url":null,"abstract":"<p><strong>Abstract: </strong>Receptors for the vasoactive adipokine apelin, termed APJ receptors, are G-protein-coupled receptors and are widely expressed throughout the cardiovascular system. APJ receptors can also signal through G-protein-independent pathways, including G-protein-coupled receptor kinase 2 (GRK2), which inhibits endothelial nitric oxide synthase (eNOS) activity and nitric oxide production in endothelial cells. Apelin causes endothelium-dependent, nitric oxide-mediated relaxation of coronary arteries from normotensive animals, but the effects of activating APJ receptor signaling pathways in hypertensive coronary arteries are largely unknown. We hypothesized that apelin-induced relaxation is impaired in coronary arteries from spontaneously hypertensive rats (SHR). Western blot and mRNA analysis revealed increased GRK2 expression in cultured SHR coronary endothelial cells. Apelin failed to cause relaxation in isolated SHR coronary arteries but, in the presence of apelin, relaxations to acetylcholine were impaired. Apelin had no effect on relaxation to diethylamine NONOate. The GRK2 inhibitor, CMPD101, increased apelin-induced phosphorylation of Akt and eNOS in SHR endothelial cells and restored relaxation to apelin in SHR arteries. CMPD101 also blocked the inhibitory effect of apelin on ACh-induced relaxation. Relaxations to the APJ receptor-biased agonist, CMF-019, which preferentially activates the G-protein-dependent pathway with minimal effect on GRK2, were similar in SHR and Wistar Kyoto coronary arteries. Immunoblot analysis in SHR coronary endothelial cells demonstrated that CMF-019 increased Akt and eNOS phosphorylation whereas apelin had no effect. Thus, APJ receptor signaling through GRK2 impairs nitric oxide production or release from SHR endothelial cells. APJ receptor-biased agonists, such as CMF-019, may be more effective than apelin in causing vasodilation of SHR coronary arteries.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"287-296"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Under Renal Replacement Therapies: Bridging the Gap Between Cardiovascular and Systemic Benefit, From Heart Failure to Myocardial Infarction.","authors":"Giuseppe Galati, Olga Germanova","doi":"10.1097/FJC.0000000000001677","DOIUrl":"10.1097/FJC.0000000000001677","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"267-269"},"PeriodicalIF":2.6,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cinnamaldehyde attenuates diabetic cardiomyopathy by ameliorating energy metabolism disturbance and activating autophagy.","authors":"Ming-Qiao Hu, Ke-Zhao Wei, Shi-Yu Wu, Xu Zhang, Xiao-Ting Zhang, Xu Xu, Xu-Hua Shen, Jian-Ping Gao","doi":"10.1097/FJC.0000000000001694","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001694","url":null,"abstract":"<p><p>Diabetic Cardiomyopathy (DCM) is a diabetes mellitus-induced pathophysiological condition that can lead to heart failure. Cinnamaldehyde (CA), a bioactive phytochemical derived from the bark of Cinnamon, exhibits cardioprotective properties against heart injury in metabolic syndrome. This study aims to explore the role of CA on DCM and its cardioprotective mechanisms. Diabetic rats were established by injection of streptozotocin (STZ, 60∼85 mg/kg). Subsequently, CA (50 mg/kg) was administered via gavage daily for 28-day duration. Following this treatment, abnormalities levels of fasting blood glucose (FBG), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and LDL-C to HDL-C ratio were ameliorated. Additionally, CA inhibited cardiac histopathological alterations and hypertrophy, reduced brain natriuretic peptide (BNP) level, shortened S-T and P-R intervals on electrocardiogram, decreased tissue malondialdehyde content, and enhanced myocardial energy metabolism, including Creatine (Cr), adenosine triphosphate (ATP), adenosine monophosphate (AMP) and total adenine nucleotides (TAN). Furthermore, CA improved oxidative stress, improved myocardial Ca2+-Mg2+-ATPase activity and downregulated the mRNA expression of AMP protein activation kinase α2 (AMPK-α2), receptor γ coactivator-1 alpha (PGC-1α) and peroxisome proliferator-activated receptor α (PPARα), while also ameliorating protein expressions, including ratio of phosphorylated mammalian target of rapamycin to mechanistic target of rapamycin (p-mTOR/mTOR), level of SQSTM1/p62, and ratio of microtubule-associated protein 1 light chain 3 beta to microtubule-associated protein 1 light chain 3 alpha (LC3Ⅱ/ LC3Ⅰ). In conclusion, these findings indicate that CA can alleviate DCM by modulating AMPK-α2/PPAR-α/PGC-1α signaling pathway to restore energy metabolism and activating autophagy through mTOR signaling pathway.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABCB1 gene single nucleotide variants and haplotypes in atrial fibrillation patients experiencing adverse events on direct oral anticoagulation: a whole gene exome sequencing study.","authors":"Matej Samoš, Mária Škereňová, Vladimír Nosáľ, Ingrid Škorňová, Tomáš Bolek, Marián Grendár, Alena Kamenišťáková, Miroslava Šarlinová, Andrea Petrovičová, Jakub Jurica, Lucia Stančiaková, Martin Péč, Erika Halašová, Egon Kurča, Juraj Sokol, Ján Staško, Marián Mokáň","doi":"10.1097/FJC.0000000000001695","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001695","url":null,"abstract":"<p><p>Single-nucleotide variants (SNVs) of ABCB1 gene encoding glycoprotein P might be connected with increased or decreased levels of direct oral anticoagulants (DOAC), and therefore with DOAC-related adverse bleeding or embolism. The aim of this study was to perform a targeted exome sequencing (TES) of ABCB1 gene in DOAC-treated patients with atrial fibrillation, who experienced a DOAC-related adverse event (AE) during the therapy. Targeted next generation sequencing was employed to examine SNVs in ABCB1 gene, which served as the basis for haplotype analysis. The study enrolled 33 patients with an AE (13 patients with bleeding and 20 patients with embolic stroke) and 33 patients tolerating long-term DOAC therapy without any AE (controls). The PLINK software was used to compare the differences between the groups. Fisher's test was employed for a standard case/control allelic association, and the chi-squared test was applied to test haplotype associations in contingency tables. In patients with DOAC-related bleeding compared with controls, no significant differences were found in all the examined SNVs; however, there were significant differences in the presence of AAAGAGCT (11.5%vs.1.6%,p<0.05) and AGAG (11.1vs.1.7%,p<0.05) haplotypes. Compared to controls, patients with stroke had a minor allele observed more frequently in rs2235033 (62.5%vs.39.4%,p<0.05), and significant differences were also found in the presence of AAAGAACT (19.3vs.39.0%,p<0.05), GGCGGGAT (19.5vs.6.4%,p<0.05), AGAA (30.8vs.51.4%,p<0.05), CGGG (23.1vs.7.6%,p<0.05) haplotypes. This study found significant differences in the selected rs2235033 SNV and in several ABCB1 gene common haplotypes in patients with DOAC-related AE.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rerouting blood flow during exercise: the emerging role of 5-HT7 receptors.","authors":"Milena Samora","doi":"10.1097/FJC.0000000000001693","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001693","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}